



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/873,415	06/05/2001	Nathan Karin	01/21982	1850
7590	07/31/2006		EXAMINER	
Martin D. Moynihan PRTSI, Inc. P.O. Box 16446 Arlington, VA 22215			SCHWADRON, RONALD B	
			ART UNIT	PAPER NUMBER
			1644	

DATE MAILED: 07/31/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/873,415	Applicant(s) KARIN, NATHAN	
	Examiner Ron Schwadron, Ph.D.	Art Unit 1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-28 and 30-55 is/are pending in the application.
 4a) Of the above claim(s) 1-12, 14, 15, 17-28 and 30-55 is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 13 and 16 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. ____. |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date ____. | 6) <input type="checkbox"/> Other: ____. |

Art Unit: 1644

1. Claims 13 and 16 are under consideration.
2. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. Claims 13 and 16 stand rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Applicants arguments have been considered and deemed not persuasive.

The specification does not provide adequate written description of the claimed invention. The legal standard for sufficiency of a patent's (or a specification's) written description is whether that description "reasonably conveys to the artisan that the inventor had possession at that time of the . . . claimed subject matter", *Vas-Cath, Inc. V. Mahurkar*, 19 U.S.P.Q.2d 1111 (Fed. Cir. 1991). In the instant case, the specification does not convey to the artisan that the applicant had possession at the time of invention of the claimed inventions.

Claims 13 and 16 recite use of "interferon gamma-inducible protein 10, or an immunological portion thereof". Regarding the term "interferon gamma-inducible protein 10" said term would encompass the aforementioned protein derived from any animal species. It appears that the only interferon gamma-inducible protein 10 known in the art is of human or mouse origin. It also appears that the term would encompass mutants and alleles of said molecule wherein the mutants or alleles are not described in the specification or prior art. The term "an immunological portion thereof" as defined in the specification, pages 33-34 clearly encompasses a massive variety of mutant peptides that are not disclosed in the specification or known in the prior art.

Thus, the skilled artisan cannot envision the detailed structure of the encompassed proteins and peptides and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the

Art Unit: 1644

method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and a reference to a potential method of isolating it. See *Fiers v. Revel*, 25 USPQ 2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. V. Chugai Pharmaceutical Co. Lts.*, 18 USPQ2d 1016.

In view of the aforementioned problems regarding description of the claimed invention, the specification does not provide an adequate written description of the invention claimed herein. See *The Regents of the University of California v. Eli Lilly and Company*, 43 USPQ2d 1398, 1404-7 (Fed. Cir. 1997). In *University of California v. Eli Lilly and Co.*, 39 U.S.P.Q.2d 1225 (Fed. Cir. 1995) the inventors claimed a genus of DNA species encoding insulin in different vertebrates or mammals, but had only described a single species of cDNA which encoded rat insulin. The court held that only the nucleic acids species described in the specification (i.e. nucleic acids encoding rat insulin) met the description requirement and that the inventors were not entitled to a claim encompassing a genus of nucleic acids encoding insulin from other vertebrates, mammals or humans, *id.* at 1240. The Federal Circuit has held that if an inventor is "unable to envision the detailed constitution of a gene so as to distinguish it from other materials. . .conception has not been achieved until reduction to practice has occurred", *Amgen, Inc. v. Chugai Pharmaceutical Co, Ltd.*, 18 U.S.P.Q.2d 1016 (Fed. Cir. 1991). Attention is also directed to the decision of *The Regents of the University of California v. Eli Lilly and Company* (CAFC, July 1997) wherein is stated:

"The description requirement of the patent statute requires a description of an invention, not an indication of a result that one might achieve if one made that invention. See *In re Wilder*, 736 F.2d 1516, 222 USPQ 369, 372-373 (Fed. Cir. 1984) (affirming rejection because the specification does "little more than outlin[e] goals appellants hope the claimed invention achieves and the problems the invention will hopefully ameliorate."). Accordingly, naming a type of material generally known to exist, in the absence of knowledge as to what that material consists of, is not a description of that material. Thus, as we have previously held, a cDNA is not defined or described by the mere name "cDNA," even if accompanied by the name of the protein that it encodes, but requires a kind of specificity usually achieved by means of the recitation of the sequence of nucleotides that make up the cDNA." See *Fiers*, 984 F.2d at 1171, 25 USPQ2d at 1606.

Regarding applicants comments, the term "interferon gamma-inducible protein 10" encompasses the aforementioned protein derived from any animal species. It appears that the only interferon gamma-inducible protein 10 known in the art is of human or mouse origin. It also appears that the term would encompass mutants and alleles of said molecule wherein the mutants or alleles are not described in the specification or prior art. The term "an immunological portion thereof" as defined in the specification, pages 33-34 clearly encompasses a massive variety of mutant peptides that are not disclosed in the specification or known in the prior art. Thus, the skilled artisan cannot envision the detailed structure of the encompassed proteins and peptides and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. **Adequate written description requires more than a mere statement that it is part of the invention and a reference to a potential method of isolating it.** See *Fiers v. Revel*, 25 USPQ 2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. V. Chugai Pharmaceutical Co. Lts.*, 18 USPQ2d 1016. In view of the aforementioned problems regarding description of the claimed invention, the specification does not provide an adequate written description of the invention claimed herein. See *The Regents of the University of California v. Eli Lilly and Company*, 43 USPQ2d 1398, 1404-7 (Fed. Cir. 1997). In *University of California v. Eli Lilly and Co.*, 39 U.S.P.Q.2d 1225 (Fed. Cir. 1995) the inventors claimed a genus of DNA species encoding insulin in different vertebrates or mammals, but had only described a single species of cDNA which encoded rat insulin. The court held that only the nucleic acids species described in the specification (i.e. nucleic acids encoding rat insulin) met the description requirement and that the inventors were not entitled to a claim encompassing a genus of nucleic acids encoding insulin from other vertebrates, mammals or humans, *id.* at 1240. The Federal Circuit has held that if an inventor is "unable to envision the detailed constitution of a gene so as to distinguish it from other materials. . .conception has not been achieved until reduction to practice has occurred", *Amgen, Inc. v. Chugai Pharmaceutical Co, Ltd.*, 18 U.S.P.Q.2d 1016 (Fed. Cir. 1991).

4. Claims 13 and 16 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

There is no support in the specification as originally filed for the recitation of "subject in need thereof" in claims 13 or 16. Regarding applicants comments about the specification, page 45, line 18, the passage to which applicant refers discloses a method of treatment using administered antibodies. The claimed invention is not a method of administering an antibody, therefore said passage is not germane to the claimed invention. According to applicants comments, page 15, last paragraph of the instant amendment, said phrase would encompass treating individuals predisposed to MS. However, there is no disclosure in the specification as originally filed of the use of the claimed method to treat patients predisposed to MS. There is no support in the specification as originally filed for the scope of the claimed invention (aka the claimed invention constitutes new matter).

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

6. Claims 13 and 16 stand rejected under 35 U.S.C. 102(b) as being anticipated by Tosato et al. (US Patent 5,994,292) as evidenced by Sportsman et al. for the reasons elaborated in the previous Office Action. Applicants arguments have been considered and deemed not persuasive.

Tosato et al. teach methods of administering IP-10 to humans (see columns 4 and 10). It is an inherent property of said methods that said methods would induce protective immunity against MS in a subject or prevent MS because the methods involve administration of the same compound recited in the claims (IP-10) to the same subjects (humans). Regarding the limitation that the dosage induces antibodies against

IP-10 to induce protective immunity against MS or to prevent MS, there is no disclosure in the specification as to what actual amount of IP-10 would be administered in vivo to a human to achieve such antibodies. Tosato et al. teach that IP-10 is administered at a wide potential range of dosages depending on the recipient (see column 8, second paragraph). Sportsman et al. teach that the art recognized that exogenously administered proteins induce antibodies in humans (see page 1623, first column, first paragraph). Thus, it would be an inherent property of the method taught by Tosato et al. that treated humans would form antibodies against IP-10. There is no disclosure in the specification that any particular level of antibody formation upon administration of IP-10 is required such that the antibodies are protective against MS.

Regarding applicants comments, in view of the fact that there is no disclosure in the specification as to what actual amount of IP-10 would be administered in vivo to a human to achieve such antibodies, it is unclear as to how applicant can argue that the dosages used by Tosato et al. would not elicit antibodies. Tosato et al. teach that IP-10 is administered at a wide potential range of dosages depending on the recipient (see column 8, second paragraph). Sportsman et al. teach that the art recognized that exogenously administered proteins induce antibodies in humans (see page 1623, first column, first paragraph). Thus, it would be an inherent property of the method taught by Tosato et al. that treated humans would form antibodies against IP-10. There is no disclosure in the specification that any particular level of antibody formation upon administration of IP-10 is required such that the antibodies are protective against MS. Furthermore, regarding applicants comments questioning the operability of the prior art, the MPEP section 716.01(c), states:

ATTORNEY ARGUMENTS CANNOT TAKE THE PLACE OF EVIDENCE

*The arguments of counsel cannot take the place of evidence in the record. In re Schulze, 346 F.2d 600, 602, 145 USPQ 716, 718 (CCPA 1965). Examples of attorney statements which are not evidence and which must be supported by an appropriate affidavit or declaration include statements regarding unexpected results, commercial success, solution of a long-felt need, **inoperability of the prior art**, invention before the date of the reference, and allegations that the author(s) of the prior art derived the disclosed subject matter from the applicant.*

Art Unit: 1644

No such evidence has been provided by applicant.

Regarding applicants comments about "a subject in need thereof", and applicants definition of said term as per identifying the subject treated as that suffering from or being predisposed to MS, there is no such definition of said term in the specification. The Examiner would interpret said term as encompassing preventative administration to any individual wherein it would be desireable to prevent MS in any individual.

7. No claim is allowed.

8. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ron Schwadron, Ph.D. whose telephone number is 571 272-0851. The examiner can normally be reached on Monday-Thursday 7:30-6:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571 272-0841. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1644

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



RONALD B. SCHWADRON
PRIMARY EXAMINER
GROUP 1800 1644

Ron Schwadron, Ph.D.

Primary Examiner

Art Unit 1644